These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35759443)

  • 21. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis.
    Li H; Xu QY; Xie Y; Luo JJ; Cao HX; Pan Q
    Ann Hepatol; 2021; 24():100316. PubMed ID: 33515803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model.
    Gorden DL; Ivanova PT; Myers DS; McIntyre JO; VanSaun MN; Wright JK; Matrisian LM; Brown HA
    PLoS One; 2011; 6(8):e22775. PubMed ID: 21857953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis.
    Vergani L
    Curr Med Chem; 2019; 26(19):3439-3456. PubMed ID: 28521680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression.
    Bellanti F; Villani R; Tamborra R; Blonda M; Iannelli G; di Bello G; Facciorusso A; Poli G; Iuliano L; Avolio C; Vendemiale G; Serviddio G
    Redox Biol; 2018 May; 15():86-96. PubMed ID: 29220698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipidomics in Nonalcoholic Fatty Liver Disease: Exploring Serum Lipids as Biomarkers for Pediatric Nonalcoholic Fatty Liver Disease.
    Draijer LG; Froon-Torenstra D; van Weeghel M; Vaz FM; Bohte AE; Holleboom AG; Benninga MA; Koot BGP
    J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):433-439. PubMed ID: 32947564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
    Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
    Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-control study in Mexico.
    Flores YN; Amoon AT; Su B; Velazquez-Cruz R; Ramírez-Palacios P; Salmerón J; Rivera-Paredez B; Sinsheimer JS; Lusis AJ; Huertas-Vazquez A; Saab S; Glenn BA; May FP; Williams KJ; Bastani R; Bensinger SJ
    Lipids Health Dis; 2021 Oct; 20(1):136. PubMed ID: 34629052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An unbiased lipidomics approach identifies key lipid molecules as potential therapeutic targets of Dohongsamul-tang against non-alcoholic fatty liver diseases in a mouse model of obesity.
    Park SH; Lee JE; Lee SM; Lee J; Seo CS; Hwang GS; Jung J
    J Ethnopharmacol; 2020 Oct; 260():112999. PubMed ID: 32454173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid mediators of liver injury in nonalcoholic fatty liver disease.
    Liangpunsakul S; Chalasani N
    Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G75-G81. PubMed ID: 30383414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Pierantonelli I; Torquato P; Marinelli R; Ferreri C; Chatgilialoglu C; Bartolini D; Galli F
    Free Radic Biol Med; 2019 Nov; 144():293-309. PubMed ID: 31152791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms.
    Rodríguez-Calvo R; Samino S; Girona J; Martínez-Micaelo N; Ràfols P; García-Altares M; Guaita-Esteruelas S; Junza A; Heras M; Yanes O; Correig X; Masana L
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32899418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review).
    Wang J; Li J; Fu Y; Zhu Y; Lin L; Li Y
    Int J Mol Med; 2024 Apr; 53(4):. PubMed ID: 38362962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr -/- mice.
    Garcia-Jaramillo M; Spooner MH; Löhr CV; Wong CP; Zhang W; Jump DB
    PLoS One; 2019; 14(4):e0214387. PubMed ID: 30943218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipidomics in non-alcoholic fatty liver disease.
    Kartsoli S; Kostara CE; Tsimihodimos V; Bairaktari ET; Christodoulou DK
    World J Hepatol; 2020 Aug; 12(8):436-450. PubMed ID: 32952872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.
    Masoodi M; Gastaldelli A; Hyötyläinen T; Arretxe E; Alonso C; Gaggini M; Brosnan J; Anstee QM; Millet O; Ortiz P; Mato JM; Dufour JF; Orešič M
    Nat Rev Gastroenterol Hepatol; 2021 Dec; 18(12):835-856. PubMed ID: 34508238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
    Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
    BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.